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Abstract
Context: Thyroid dysgenesis may be associated with loss-
of-function mutations in the thyrotropin receptor (TSHR) 
gene.
Objectives: The aim of this study was to characterize a 
novel TSHR gene variant found in one patient harboring 
congenital hypothyroidism (CH) from a cohort of patients 
with various types of thyroid defects.
Materials and methods: This cross-sectional cohort study 
involved 118 patients with CH and their family members, 
including 45 with familial and 73 with sporadic diseases. 
The thyroid gland was normal in 23 patients, 25 patients 
had hypoplasia, 25 hemithyroid agenesis, 21 had athyreo-
sis, and 21 had ectopy. Genomic DNA was extracted, and 
10 exons of the TSHR gene were amplified and sequenced. 
Mutations in other candidate genes were investigated. 
Ortholog alignment was performed, and TSHR functional 
assays were evaluated.
Results: We identified one previously unknown missense 
variation in the hinge region (HinR) of the TSHR gene 
(p.S304R) in one patient with thyroid hypoplasia. This 
variant is conserved in our ortholog alignment. However, 
the p.S304R TSHR variant presented a normal glycosyla-
tion pattern and signal transduction activity in functional 
analysis.
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Conclusion: We report the ocurrence of a novel nonsyn-
onymous substitution in the HinR of the large N-terminal 
extracellular domain of the TSHR gene in a patient with 
thyroid hypoplasia. In contrast with four others in whom 
TSHR mutations of the hinge portion were previously 
identified, the p.S304R TSHR variation neither affected 
TSH binding nor cAMP pathway activation. This TSHR 
gene variant was documented in a CH patient, but the cur-
rent data do not support its role in the clinical phenotype.
Keywords: congenital hypothyroidism; hinge portion; 
thyroid dysgenesis; TSH receptor; variants.
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Introduction
Thyrotropin (TSH) exerts its effects on the thyroid cell by 
binding to specific receptors on the cell surface (1). The 
thyrotropin receptor (TSHR) belongs to the superfamily 
of seven-transmembrane receptors that trigger signal-
transduction pathways through their synergy with gua-
nine-nucleotide-binding regulatory proteins (G proteins) 
(1–4). As such, they contain a canonical serpentine region 
containing seven transmembrane helices typical of rho-
dopsin-like glycoprotein hormone receptor (GPCRs), and 
a large (350–400 residues) amino-terminal ectodomain 
containing leucine-rich repeats, which is responsible 
for the high affinity and selective binding of the corre-
sponding hormones (1). The amino-terminal segment is 
responsible for high affinity binding of the hormones and 
recognition specificity (5). The hinge region (HinR) is the 
least conserved GPCR portion and the most variable in 
size, between the extracellular leucine-rich repeat motif 
and the transmembrane helices (6–10). The importance of 
this region for hormone binding, signal transduction, and 
receptor activation has been indicated in several studies; 
however, the hormone TSHR interaction mechanisms 
have yet to be completely understood (8–10). The intramo-
lecular transduction mechanism of the signal, by which 
binding of TSH to the extracellular region of the receptor 
is transduced via the membrane-spanning regions to the 
cytoplasmic compartment of the receptor that interact 
with the G proteins, is not well known. A current model for 
the activation of TSHR would examine a zone of discrete 
states characterized by different configurations (2, 3).
In the frame of our discussion, it is worth noting that 
amino acid substitutions in the ectodomain of GPCRs 
might affect their function by modifying the electrostatic 
surface map of the variant receptor, thereby leading to a 
loss of specificity, or affinity through a shift on sialylated 
and sulfated carbohydrate structure (1, 11).
Germline TSHR loss-of-function mutations in the TSHR 
gene have been involved as the molecular answer for TSH 
resistance and congenital hypothyroidism (CH) (OMIM 
no. 275200). Subjects with a heterozygous loss of function 
mutation appear to have a dominant transmission of partial 
TSH resistance, which is attributed to intracellular entrap-
ment, reduced maturation, and oligomerization between 
inactive mutants and the WT receptor (12–16). Indeed, in 
the past years, many germline TSHR variants, culminat-
ing in amino acid substitutions have been discovered (12). 
Two of these are located in the extracellular domain of the 
receptor (p.D36H and p.P52T), and one is located in the 
intracellular domain (p.D727E) (17–19). The TSHR variant 
p.D727E allele associated with lower levels of plasma TSH 
without effect on FT4 levels, point toward a higher sensi-
tivity of the variant compared with the WT TSHR. This is 
because less TSH is needed to achieve normal FT4 levels, 
as reported in two studies (20, 21). However, others have 
not been able to reproduce such data (22, 23). Despite the 
fact that the p.P52T and p.D36H polymorphisms have not 
been correlated with modifications in serum TSH levels 
in healthy individuals, conflicting data are also available 
regarding the response of the extracellular domain p.P52T 
variant to TSH stimulation (24, 25).
In the current study, we report a novel germline 
variant, p.S304R, located in the hinge region (HinR) of 
the extracellular domain of the TSHR, which is present in 
heterozygocity in a patient with congenital hypothyroid-
ism. We examined the functional properties of this variant 
by transient expression in HEK293 cells, with particular 
interest in the effect on binding ability, cAMP production, 
and glycosilation profile. The knowledge about the con-
tribution of systematically conserved residues within the 
TSHR HinR to hormone binding is very important in the 
further clarification of their precise functional importance 
in hormone-receptor interactions.
Materials and methods
Subjects
We enrolled 118 patients with CH, including 45 with familial and 73 
with sporadic diseases recruited from the French Neonatal Screen-
ing Program, along with their family members (Table 1). The thy-
roid gland was normal in size and position in 23 of these patients; 
92 patients had hypoplasia (n = 25), hemithyroid agenesis (n = 25), 
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Table 1 Patient characteristics.
Variable  
Number, male, female   118 (47, 71)
Age, year, median, range   11.0 (1.1–23.2)
Family history of CH, n   45
Sporadic cases of CH, n   73
Blood-spot TSH at screening, 
mU/L, median, range
  72.9 (16.9 to  > 200)
Thyroid morphology, n  
 Ectopy   21
 Athyreosis   21
 Hypoplasia   25
 Hemithyroid   25
 Normal   23
 Not evaluated   03
Kidney malformation   07
CH, congenital hypothyroidism.
athyreosis (n = 21), or ectopy (n = 21); and thyroid gland morphology 
was unknown in three patients. Informed consent was obtained from 
all patients and their families, and blood samples were collected. The 
study was approved by the local Ethical Committee.
TSHR sequencing
Genomic DNA was extracted from whole blood, and 10 exons of the 
TSHR gene were amplified in 15 separate PCRs (26). PCR products were 
purified using the Qiaquick PCR purification kit (QIAGEN, Hilden, 
Germany) and sequenced using the ABI PRISM Dye Terminator cycle 
sequencing Ready Reaction kit (PE Applied Biosystems, Foster City, 
CA, USA) according to the manufacturers’ instructions. Sequences 
were analyzed using Sequence Navigator Software (PE Applied Bio-
systems Division, Perkin Elmer, Foster City, CA, USA). Bidirectional 
sequencing was performed using an automated cycle sequencer (ABI) 
Prism 3100 Genetic Analyzer (Applied Biosystems, Vernon Hills, IL, 
USA). Sequence alterations were examined in the context of the open 
reading frame to determine whether the alteration changed the corre-
sponding amino acid. A total of 100 normal individuals were screened 
for the identified sequence alterations. Mutations in other candidate 
genes (PAX8, NKX2.1, NKX2.5) were excluded.
Annotation of the human TSHR protein
Genbank accession no. NP_16473 (www.ncbi.nlm.nih.gov) was used 
for the human TSHR protein reference. Exon positions were calcu-
lated from the annotation at the University of California, Santa Cruz, 
Genome Browser (http://genome.ucsc.edu).
Prediction of TSHR orthologs and alignment 
with human TSHR sequence
The corresponding proteins for each of the 11 non-human species 
(Pan troglodydes, Macaca mulatta, Rattus norvegicus, Mus musculus, 
Bos taurus, Dasypus novemcinctus, Monodelphis domestica, Gallus 
gallus, Xenopus tropicalis, Takifugu rubripes and Orysias latipes) used 
in this study were obtained as described here. First, the genomic 
sequence was obtained from all species; second, protein predic-
tions were obtained for each DNA sequence using GENSCAN soft-
ware (http://bioweb.pasteur.fr/seqanal/interfaces/genscan-simple.
html) (27) and default parameters; third, results from GENSCAN 
were compared with the NP_16473 reference sequence using BLAST 
(www.ncbi.nlm.nih.gov) (28) to identify TSHR orthologs; and fourth, 
TSHR protein orthologs were aligned to the human reference using 
CLUSTALW (http://clustalw.genome.ad.jp) (29). Accession numbers 
corresponding to all sequences used in this study are provided under 
solicitation.
TSHR-S304R functional studies
Western-blot analysis and 125I-TSH binding experiments were per-
formed as previously described (30). Accumulation of cAMP was 
measured using the cAMP dynamic 2 kit (Cisbio Bioassays, Bagnols-
sur-Cèze, France) according to the manufacturer’s instructions. Tran-
sient HEK293-cell transfection with plasmid-encoded TSHR-WT or 
TSHR-S304R was performed, and 48  h later the cells were washed 
once with phosphate buffer saline (PBS) and detached with PBS-
ETDA 5 mM. The cells were then resuspended in stimulation buffer 
(Krebs buffer with 0.28 M sucrose) and plated in 384-well plates. The 
cells were stimulated for 30 min with various TSH concentrations in 
stimulation buffer, which was upplemented with 0.5  mM of IBMX. 
After stimulation, fluorophore d2-labeled cAMP and anti-cAMP anti-
body conjugated to cryptate were added and incubated for 1 h at room 
temperature, and the plate was read at 620 nm and 665 nm using the 
PARADIGM™ Detection Platform (Beckman Coulter, Brea, CA, USA). 
Data were analyzed using GraphPad Prism Software (GraphPad, San 
Diego, CA, USA).
Results
Genetic screening and clinical phenotype
The family pedigree has been previously described (31). 
Direct TSHR gene sequencing identified one different 
heterozygous TSHR variant (p.S304R) in three family 
members: the proposistus, his father, and the older 
brother (Figures 1 and 2A). The affected boy is the second 
child of healthy, nonconsanguineous parents and was 
born at term, following an uncomplicated pregnancy and 
delivery, with a weight of 3.400 kg. Neonatal TSH screen-
ing showed a TSH level of 155 μU/mL (normal  < 20 μU/mL) 
and an FT4 level of 0.8 ng/dL (normal 0.8–1.8). He pre-
sented jaundice, mild hypotonia, and a large posterior 
fontanelle. LT-4 therapy was started at 13  days of age. 
By 18  days of age, a 123I scintigraphy showed a hypo-
plastic gland in normal position (Figure  1). The parents 
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Figure 1 Partial alignment of the human TSHR N-terminal hinge region with amino acid conservation.
Sequencing alignment from different species shows the status of conservation of the mutated amino acid residue. This human TSHR 
sequence includes 31 amino acid residues located within the HinR of the TSHR gene and multiple sequence alignments with 11 orthologs. 
The shaded boxes indicate the position of the reported p.S304R variant.
were clinically unaffected, but biological investigations 
showed moderate TSH elevation in the father (TSH, 
6.2 μU/mL; normal: 0.4–4.5) with an FT4 level of 1.0 ng/dL 
(normal: 0.8–1.8). The propositus’ brother had a normal 
thyroid gland at ultrasound and normal thyroid function 
tests with a TSH of 2.5 μU/mL (normal: 0.4–4.5). Subse-
quent analysis of the direct family members revealed that 
his paternal grandmother had medical history of a mild 
high TSH of 9.4 μU/mL (normal: 0.4–4.5). By 5 years old, 
thyroid ultrasound revealed a very hypoplastic thyroid 
gland. Clinical assessment to date reveals normal growth 
and development. All family members were studied for 
mutation in other known candidate genes for thyroid dys-
genesis. The patient’s father and brother have a normal 
PAX8 coding sequence, and there were no other TSHR 
sequence variations among the members of this family. 
The propositus was heterozygous for the previously 
reported p.R31C PAX8 mutation as previously reported in 
other studies (31–33). The p.S304R variant was not found 
in 100 normal individuals.
Ortholog alignment
Our analysis rests on the idea that the differences in 
standard physicochemical properties between the “wild-
type” amino acid and the missense variant are the root 
cause of functional impairment, and that evolutionary 
variation among orthologs in the affected position is 
a sample of the physicochemical properties tolerated 
at that position. We first built a multiple alignment of 
orthologs with ClustalW2 (Figure 1) (34); paralogs were 
excluded to avoid including evolutionary variation that 
specified functional differences. We have predicted 
orthologous TSHR protein sequences from the genomic 
sequences of 11 non-human vertebrate species, includ-
ing two primates, one artiodactyl, one carnivore, three 
rodents, one bird, one amphibian and two teleosts 
species, successfully aligning all to the human refer-
ence (Figure 1). The corresponding proteins for each of 
the abovementioned species were identified and aligned 
(Figure 1). As expected, maximal identity was observed 
between the reference (human) and the most recently 
diverged species, the non-human primates. Similarity 
decreased as we progressed through the mammalian 
radiation to greater evolutionary distances, and was at 
its lowest as we reached the avian and teleost species.
Functional studies of TSHR-S304R
Substitution of an arginine for serine 304 modified the 
consensus sequence of an N-glycosylation site (NXS/T), 
changing the 302NES304 sequence to 302NER304. The gly-
cosylation status of the S304R-mutated TSHR gene 
(S304R-TSHR) was determined by Western blot, with an 
antibody directed against the extracellular domain of 
TSHR. In protein extracts from cells transiently express-
ing WT-TSHR, this antibody revealed two bands cor-
responding to the high-mannose form at 95  kDa and 
to the alpha subunit at 56  kDa (35). After deglycosyla-
tion by endoglycosidase F (EndoF), which removed all 
complex sugars from the N-glycosylation site, two bands 
appeared, at 80 and 37 kDa, respectively (Figure 2B). In 
membrane proteins extracted from HEK293 cells tran-
siently expressing S304R-TSHR, two bands were also 
detected, but their molecular weights were slightly lower 
than those observed for WT-TSHR (Figure 2B). These dif-
ferences between S304R-TSHR and WT-TSHR disappeared 
after EndoF treatment. Therefore, the S304R substitution 
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Figure 2 Functional analysis of the S304R-TSHR variant in transiently transfected HEK293 cells.
(A) Chromatograms showing the heterozygous p.S304R TSHR variant found in family 2. (B) Analysis of the glycosylation profile of WT-TSHR 
and S304R-TSHR by Western immunoblotting with and without EndoF treatment. The high-mannose immature form (arrow) and the alpha 
subunit (arrowhead) of TSHR are shown. (C) I125-TSH competitive binding curve with intact cells transiently expressing WT-TSHR (black 
square) or S304R-TSHR (open circle). (D) cAMP production in HEK293 transiently expressing WT-TSHR (black square) or S304R-TSHR (open 
circle). Each point represents the mean ± SEM of hexaplicates.
disrupted N-glycosylation of asparagine 302 (Figure 2B). 
Functional analyses showed that the S304R substitution 
affected neither TSH binding to TSHR nor adenylate-
cyclase pathway activation, thus indicating that neither 
N-glycosylation of N302 nor 302NES304 sequence was criti-
cal for TSHR function (Figures 2C and 2D).
Discussion
In a CH patient, we identified a novel heterozygous ger-
mline point mutation, at codon 304, which resulted in 
the substitution of a serine for an arginine (p.S304R) of 
the TSHR. The mutant receptor was transiently expressed 
in HEK293 cells and caused equivalent activation of the 
cAMP pathway when compared with the WT TSHR (Figure 
2). The p.S304R variant was identified in only one of the 
440 chromosomes analyzed in this cross-sectional study 
and control population. Therefore, this variation is not 
considered polymorphism but may be considered a rare 
sequence variant instead. The analysis of amino acid 
residue serine in the position 304 of the protein of the 
TSHR gene showed conservation among Homo sapiens, 
Macaca mulatta, Rattus norvegicus, Mus musculus, Bos 
taurus, Dasypus novemcinctus and Monodelphis domestica 
(Figure 1). However, although mutational analyses may 
be significantly enhanced by deep evolutionary sequence 
comparisons, they may not account for all sources of func-
tional constraint and phenotypic impact.
The TSHR ectodomain can be subdivided into leucine-
rich repeat (LRR) and the HinR, which links the LRR with 
the serpentine domain and is assumed to be represented 
by amino acids placed between positions 280 and 410, 
which contain multiple possible TSH binding sites (9). 
Therefore, it was likely that the change of a polar hydro-
philic S304 into a positive charged arginine residue dis-
rupted the HinR structure, leading to a reduction in the 
receptor binding capacity. The p.S304R variant is located 
in a glycosilation HinR position within the onset of the of 
the cysteine box 2/3 linker region, which is known to be 
responsible to connect the N- and C-terminally located 
cysteine boxes [cysteine box 2 (C-b2) and Cysteine box 3 
(C-b3)] (36). The value of the C-b2/3 linker in the main-
tenance of the signaling competence of the receptor has 
been revealed by several studies (5, 36). More specifically, 
the role for the serine in the 304 position has been explored 
and its substitution for alanine (p.S304A mutant) had 32% 
reduction in the expression and a slight but significant 
impairment (15%) in binding both bovine TSH (bTSH) and 
TR1401 (a human TSH analog) (10). Nevertheless, another 
study confirmed that p.S304A had decreased cell surface 
expression and transfection efficiency by FACS analysis, 
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Table 2 Spectrum of clinical features and functional effects in patients with TSHR gene missense mutations located at the hinge portion 
identified to date.
Protein   No. of cases  Genotype  Thyroid 
morphology
  Thyroid 
function
  Functional analysis of the 
mutations
  References
S304R   1  HET   Hypoplasia   CH   nl cAMP   Present 
study          nl Glycosilation  
R310C   5a  3 HET   nl   MH   ↓ TSH Binding   (44)
    2 HOM     SH   ↓ cAMP  
  1  HET   Nl   MH     (40)
C390W   1  HET   enlarged   MH   ↓ Expression at cell surface   (26)
  3a  2 HET   nl   MH   ↓ TSH binding   (40)
          ↓ cAMP  
  4a  3HET   nl   EU    
    1HOM   Hypoplasia   CH     (36)
  1  HET   na   MH     (37)
D403N   1  HET   na   MH   ↓ TSH binding   (38)
  2a  HET   na   EU, IH   ↓ Expression at cell surface   (39)
          ↓ cAMP  
  2a  HET   Hypoplasia   MH, IH     (40)
  1  HET   na   IH     (41)
  1  CHET   na   CH     (43)
D410N   2a  HET   nl   MH, IH    = TSH Binding   (40)
          ↓ cAMP  
  1  CHET   nl   MH     (26)
  2a  HET   nl   IH     (45)
           
Adapted from Cassio et al. (12) and Persani et al. (46). EU, euthyroidism; IH, isolated hyperthyrotropinemia; MH, mild hypothyroidism; SH, 
severe hypothyroidism; CH, congenital hypothyroidism; HOM, homozygous; HET, heterozygous; CHET, compound heterozygous. aMember of 
the same family. na, not given; nl, within normal limits.
but the basal and stimulated cAMP accumulation were 
normal compared with WT receptor (36).
Actually, the cysteine box 2/3 linker region and C-ter-
minal portion of HinR harbor other previously described, 
naturally occurring inactivating mutations (p.R310C, 
p24X, p.C390W, p.D403N, and p.D410N), and site-directed 
mutagenesis studies have demonstrated that even the 
replacement of a single amino acid residue (e.g., p24X, 
p.C390W, and p.D403N) can severely impair the expres-
sion of a functional receptor protein (26, 37–43) (Table 2). 
Most described patients with a TSHR mutation within the 
HinR have a thyroid of reduced size, suggesting that this 
region plays an important role in the signal transduction 
and, consequently, in the thyroid gland growth (Table 2) 
(26, 37–45, 47).
Meanwhile, the mutations p.R310C and p.C390W 
are related with impaired binding and cAMP genera-
tion, confirming the hypothesized inhibitory effect of the 
extracellular domain on a noisy transmembrane; this 
also explains the compensated TSH resistance in affected 
patients. On the one hand, the mutation D410N has 
been reported to be associated with normal binding but 
defective cAMP generation, and such findings confirm the 
role of the HinR in conveying the signal from the extra-
cellular domain to the serpentine domain. On the other 
hand, our functional analysis could express cDNA for the 
WT and the p.S304R receptor variant in HEK293 cells. The 
125I-thyrotropin binding capacity analysis also showed 
that both forms exhibited similar specific and saturable 
binding of thyrotropin and the amount of expressed cells 
on the surface (Figure 2B–D). Further, the aditional func-
tional characterization of the TSHR-S304R variant showed 
that the absence of one N-glycosylation site did not modify 
receptor function (Figure 2B). In this context, the p.S304R 
hinge variant does not seem to be functionally important, 
and the described dysgenetic phenotype would only be 
explained by the heterozygous p.R31C mutation, which 
was exclusively found in the propositus patient. The del-
eterious effect of PAX8 mutation has already been demon-
strated (33). We can assume that the wearing 2 mutations 
on the PAX8 and TSHR synergize default size and func-
tional thyroid.
Understanding the structure and function of the HinR 
is an important step in achieving a complete picture of the 
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necessary mechanisms for the TSHR activation and sign-
aling. Recent reports have shown that the HinR is not only 
a scaffold for maintaining binding of the glycoprotein hor-
mones, but may also work as an important signal trans-
mitter for TSH-induced activation.
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